Table 5.
KEGG Enrichment Pathways for the Set of 628 Gene Targets Derived from the Combination of at Least Two miRNAs
| Pathway | Enrichment p-value | Genes |
|---|---|---|
| MicroRNAs in cancer | 5.75e-10 | TGFB2,ABL1,CRKL,MAPK1,DICER1,MMP9,CCND1,E2F3,VEGFA, CCNG1, GLS, CCND2, CDKN1A, MDM2, MYC, THBS1, CYP1B1, MCL1, BCL2L11, CDC25A, CRK, DDIT4, STAT3, IRS1, BCL2, PTEN, BMPR2 |
| FoxO signaling pathway | 4.24e-05 | TGFB2, MAPK1, TGFBR1, CCND1, FOXO3, CCND2, CDKN1A, PRKAB2, MDM2, IL6, IGF1R, SETD7, PIK3R1, BCL2L11, TGFBR2, STAT3, IRS1, PTEN, USP7 |
| Cellular senescence | 0.000151 | MRE11A, TGFB2, MAPK1, TGFBR1, CCND1, E2F3, FOXO3, CCND2, CDKN1A, MDM2, IL6, MYC, PIK3R1, IGFBP3, HIPK1, TGFBR2, CDC25A, BTRC, PTEN, PPP3R1 |
| p53 signaling pathway | 0.000208 | SESN1, CCND1, CCNG1, CCND2, APAF1, TNFRSF10B, CDKN1A, MDM2, THBS1, IGFBP3, BCL2, RRM2, PTEN |
| Chronic myeloid leukemia | 0.000393 | TGFB2, ABL1, CRKL, MAPK1, TGFBR1, CCND1, E2F3, CDKN1A, MDM2, MYC, PIK3R1, TGFBR2, CRK |
| AGE-RAGE signaling pathway in diabetic complications | 0.00166 | EDN1, ICAM1, TGFB2, MAPK1, TGFBR1, CCND1, VEGFA, EGR1, IL1B, IL6, PIK3R1, TGFBR2, STAT3, BCL2 |
| Bladder cancer | 0.00156 | MAPK1, MMP9, CCND1, E2F3, VEGFA, CDKN1A, MDM2, MYC, THBS1 |
| HIF-1 signaling pathway | 0.00209 | TFRC, EDN1, MKNK2, MAPK1, PGK1, VEGFA, CDKN1A, PDHA1, IL6, IGF1R, PIK3R1, HK2, STAT3, BCL2 |
| Hepatitis B | 0.0024 | MAVS, TGFB2, MAP3K1, MAPK1, MMP9, TGFBR1, CCND1, E2F3, APAF1, CDKN1A, IL6, MYC, PIK3R1, YWHAZ, STAT3, BCL2, PTEN |
| Focal adhesion | 0.00499 | BIRC3, VCL, ITGA6, CRKL, MAPK1, ITGB8, RAPGEF1, CCND1, VEGFA, CCND2, ROCK2, THBS1, IGF1R, PIK3R1, CRK, CTNNB1, PTK2, BCL2, PTEN, PAK2 |
| Thyroid cancer | 0.00527 | TPR, MAPK1, CCDC6, CCND1, CDKN1A, MYC, CTNNB1, NCOA4 |
| Cell cycle | 0.00548 | SMC1A, TGFB2, ABL1,CCND1, MCM3, E2F3, CCND2, CDKN1A, MDM2, MYC, CDC25A, YWHAZ, WEE1, YWHAG, PRKDC |
| Pathways in cancer | 0.00559 | BIRC3, TPR, HSP90AA1, ITGA6, TGFB2, ABL1,CRKL,MAPK1,MMP9, JAG1,TGFBR1, CCDC6, CCND1, E2F3, VEGFA, CCND2, GNA13, APAF1, NCOA3, CDKN1A, ROCK2, IL6ST, MDM2, IL6, MYC,I GF1R, PIK3R1, BCL2L11, GNAQ, APPL1, TGFBR2, CRK, CTNNB1, STAT3, PTK2, BCL2, PTEN, NCOA4 |
| Colorectal cancer | 0.00768 | TGFB2, MAPK1, TGFBR1, CCND1, CDKN1A, MYC, PIK3R1, BCL2L11, APPL1, TGFBR2, CTNNB1, BCL2 |
| Hippo signaling pathway | 0.0195 | MPP5, TGFB2, SMAD7, TGFBR1, CCND1, CCND2, PARD6B, MYC,YAP1, TGFBR2, YWHAZ, BTRC, CTNNB1, YWHAG, NF2, BMPR2 |
| Endocrine resistance | 0.0203 | MAPK1, MMP9, JAG1, CCND1, E2F3, NCOA3, CDKN1A, MDM2, IGF1R, PIK3R1, PTK2, BCL2 |
| Prostate cancer | 0.0248 | HSP90AA1, MAPK1, MMP9, CCND1, E2F3, CDKN1A, MDM2, IGF1R, PIK3R1, CTNNB1, BCL2, PTEN |
| Platinum drug resistance | 0.0318 | REV3L, BIRC3, MAPK1, APAF1, CDKN1A, TOP2A, MDM2, SLC31A1, PIK3R1, BCL2 |
| Pancreatic cancer | 0.0496 | TGFB2, MAPK1, TGFBR1, CCND1, E2F3, VEGFA, CDKN1A, PIK3R1, TGFBR2, STAT3 |